Pharma BD Deal Intelligence
GlaxoSmithKline and Vir aim to take on Covid-19 with monoclonal antibodies and CRISPR screening technology against SARS-CoV-2
GlaxoSmithKline doubles down on Vir pact throwing $345M upfront to expand collaboration beyond COVID-19 into influenza and respiratory viruses
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
GSK and Vir Biotechnology partnered to co-develop monoclonal antibodies for coronaviruses, leading to sotrovimab for COVID-19 and later expanding to influenza therapeutics.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Vir Biotechnology Inc. (this deal) | 2020 | $595M | 51 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Reliant Pharmaceuticals Inc. | 2007 | $1.6B | 47 |
← Browse all deals · How we score deals
More: 2020 deals · GlaxoSmithKline plc deals · Infectious Disease deals